ARMR Sciences
New York, US · Founded 2023 · Delaware corporation · 1 known investors
Find your way into ARMR Sciences
Sign up to see every warm intro you have to ARMR Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ARMR Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]
Founders & leadership
ARMR Sciences was founded in 2023 by David Dowling.
Investors · 1
How we know: Daft Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements▶$30MofferedAug 2025 · BiotechnologyRule 506(c)
- Shon RemichExecutive Officer
- Jeffrey HwangDirector
- Nicholas JacobExecutive Officer
- Collin GageExecutive Officer, Director
- Kenneth KohnDirector
- Denise ShullDirector
- Offering amount
- $30M
- Minimum investment
- $5K
- Placement agents
- Digital Offering, LLC
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as ARMR Sciences.
In the news
Frequently asked questions
- What does ARMR Sciences do?
- ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]
- Who founded ARMR Sciences?
- ARMR Sciences was founded by David Dowling in 2023.
- Who are ARMR Sciences's investors?
- ARMR Sciences's investors include Daft Capital.
- Where is ARMR Sciences headquartered?
- ARMR Sciences is headquartered in New York, US.







